Status:

UNKNOWN

Povidone Iodine Nasal Irrigation and Gargling to Reduce Viral Load in Asymptomatic Patients With COVID-19

Lead Sponsor:

Ruijin Hospital

Conditions:

2019 Novel Coronavirus Infection

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The emergence of a novel coronavirus(SARS-CoV-2) in late 2019 has resulted in a global epidemic of the infectious condition COVID-19. Since March 2022, the Omicron mutant has caused widespread transmi...

Detailed Description

The purpose of the study is to evaluate if using nasal irrigation and gargling with PVP-I and hypertonic saline solution, can improve the negative conversion rate of SARS-CoV-2 nucleic acid on day 10 ...

Eligibility Criteria

Inclusion

  • Patients nucleic acid testing positive for COVID-19.
  • Diagnose as asymptomatic patients infected by COVID-19, and receive medical observation at a Fang Chang Hospital.
  • Be able to understand this study, willing to participate in, and sign the informed consent form.
  • Commit to follow the research procedures and cooperate in the implementation of the whole process research.
  • Can communicate with researchers through smart phones.

Exclusion

  • The nucleic acid test result of novel coronavirus has always been negative after entering the Fang Chang Hospital.
  • patients who have history of nasal surgery, or current use of nasal saline irrigation or other intranasal medications.
  • Patients with thyroid diseases , respiratory diseases or other serious basic diseases.
  • Allergy to iodine.
  • Participation in another prospective COVID related research project(clinical trial).
  • Pregnancy or lactation
  • Patients with immune deficiency (such as patients with malignant tumors, organ or bone marrow transplantation, patients with AIDS, and those taking immunosuppressive drugs within 3 months before screening).
  • Other patients considered unsuitable by the investigator to participate in this study

Key Trial Info

Start Date :

April 16 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 31 2022

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT05375773

Start Date

April 16 2022

End Date

October 31 2022

Last Update

May 24 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Ruijin Hospital,Shanghai Jiaotong University school of medicine

Shanghai, Shanghai Municipality, China